Novo Nordisk has partnered with Lifera (April 2025), a Saudi-funded biotech platform, to localise manufacturing as part of Saudis National Biotech Strategy and is expected to be a preferred supplier
People who used GLP-1 medications including Ozempic, Trulicity, Wegovy, Saxenda, Victoza, Mounjaro, Rybelsus, or Zepbound and were diagnosed with NAION or experienced sudden vision loss in one eye may be eligible for compensation.
And for those engaged in this cutting-edge work, access to a pure, reliable version of the molecule is non-negotiable
Nearly 90% of those who continued maintained at least 80% of their earlier loss, compared with 16.6% after withdrawal
Most published data derive from small pilot studies, in vitro experiments, and animal research, which substantially limits the conclusions that can be drawn
S.EscobedoB.HaiderM.MekonenY.FerrerD.HillyardS